Monitoring device trial for stable heart failure symptoms
Part of Heart & circulation clinical trials.
This trial tests whether a wearable home monitoring system (myCordella™) can help people with moderate heart failure (NYHA class II or III) by tracking heart pressure and supporting follow-up care. It may help detect changes earlier so clinicians can adjust treatment sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and can give written consent
- You have heart failure (HF) diagnosed for at least 3 months and are NYHA class II or III
- Your heart failure medicines have been stable for at least 30 days (or you can’t take them due to documented reasons)
- You’ve had HF-related hospitalization recently if you’re in the NYHA II or NYHA III group
- You take a diuretic (“water pill”) for at least 1 month (at a dose equivalent to 40 mg furosemide or more)
- You can safely use the myCordella™ Patient Reader at home and come back for scheduled visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a combination of a tiny lung-artery pressure sensor (CardioMEMS) and a mechanical heart pump (HeartMate 3) is safe and effective for people with advanced heart failure. If you qualify, you'll either get the heart pump plus standard medical therapy, or continue with standard therapy alone and have your pressure monitored remotely.
This trial studies a small sensor placed in the lung artery to help manage chronic heart failure. It compares patients who get the sensor to those who receive standard care, to see if the sensor improves outcomes.
This study tests whether a wearable device that monitors your heart and transmits data to your doctor can help optimize your heart failure medications after hospitalization. The goal is to prevent future hospital visits and improve your health by keeping closer tabs on how your body responds to treatment adjustments.
This study tests whether a CardioPulmonary Management (CPM) system device used at home is safe and can improve outcomes for people with chronic heart failure. It may help manage symptoms and reduce complications, especially for higher-risk patients.
This trial tests whether remote monitoring of your implanted heart device can help your doctors better manage your heart failure. It is for people with certain types of pacemakers or defibrillators who are willing to share their device data remotely.
This trial tests a home monitoring system called Cardiosignal to help manage heart failure after an emergency room visit. It may help doctors adjust your treatments to keep you healthier at home.
Hear when a new Heart Failure NYHA Class II trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.